Aflibercept in wet AMD: specific role and optimal use
Open Access
- 1 August 2013
- journal article
- review article
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. 7, 711-722
Abstract
Peer reviewed article authored by (Semeraro F, Morescalchi F, Duse S, Parmeggiani F, Gambicorti E, Costagliola C). Read article or submit your manuscript for publishing.Keywords
This publication has 78 references indexed in Scilit:
- Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumabAngiogenesis, 2012
- The Expanding Role of Vascular Endothelial Growth Factor Inhibitors in OphthalmologyMayo Clinic Proceedings, 2012
- PHARMACOKINETIC RATIONALE FOR DOSING EVERY 2 WEEKS VERSUS 4 WEEKS WITH INTRAVITREAL RANIBIZUMAB, BEVACIZUMAB, AND AFLIBERCEPT (VASCULAR ENDOTHELIAL GROWTH FACTOR TRAP-EYE)Retina, 2011
- Ranibizumab and Bevacizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2011
- Inflammatory Mediators and Angiogenic Factors in Choroidal Neovascularization: Pathogenetic Interactions and Therapeutic ImplicationsMediators of Inflammation, 2010
- TACHYPHYLAXIS AFTER INTRAVITREAL BEVACIZUMAB FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATIONRetina, 2009
- Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trialBritish Journal of Ophthalmology, 2008
- Ranibizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006
- The Price of Sight — Ranibizumab, Bevacizumab, and the Treatment of Macular DegenerationNew England Journal of Medicine, 2006
- Angiogenesis in life, disease and medicineNature, 2005